Key Developments:
Virelink-B (09887): The Phase II clinical trial of Vilexin® (Opasutsumab, a PD-L1/4-1BB bispecific antibody, LBL-024) as a first-line treatment for ESCC has entered the expansion phase.
Hengrui Medicine (01276): The drug marketing authorization application for HRG2010 capsules has been accepted.
Leader Education (01449) has agreed with NeuralFin to establish a strategic partnership in the field of artificial intelligence (AI) education.
Shanghai Pharmaceuticals (02607) plans to transfer its 51% equity stake in Shanghai Pharma Xinte Dong'an Pharmacy through a public listing.
Baoji Pharmaceutical-B (02659): The clinical trial application for KJ015 injection (an anti-HER2 bispecific antibody subcutaneous formulation) has received FDA clearance in the United States.
Changfeng Pharma (02652): ICF001 has expanded its indicated scope after receiving implied approval for clinical trials from the National Medical Products Administration.
XPeng Group-W (09868): Pengxing has secured USD 600 million in A-series preferred shares through subscriptions from IDG Capital, Alibaba, Tencent, and GSR Ventures.
Operating Results:
Viewtrix Tech (03310) has released its interim results, with revenue reaching RMB 318 million, as it deepens its focus on the branded AMOLED display driver chip market.
ABBISKO-B (02256): In the first half of the year, its core drug Beijemai® achieved successful commercialization, while R&D spending continued to increase.
Qingsong Health (02661) reported in its interim report that revenue from comprehensive health services grew by 273.5%, with medical AI accelerating its path toward practical applications.
China Railway Signal & Communication (03969) has announced its interim results, with net profit attributable to shareholders reaching approximately RMB 1.473 billion, a decrease of 9.07% year-on-year.
Luxshare Precision (02475) has published its interim results, with net profit attributable to shareholders at approximately RMB 7.843 billion, up 18.04% year-on-year.
Jiazuo Property (02168) has released its interim results, with shareholder profit attributable of RMB 41.873 million, a decline of 12.4% year-on-year.
CSSC Leasing (03877) has released its interim results, with shareholder profit attributable of HKD 1.222 billion, an increase of 10.6% year-on-year.
Wuxi XDC (02268) has announced its interim results, with adjusted net profit attributable to owners of the company at approximately RMB 1.027 billion, up 37.4% year-on-year.
XPeng Group-W (09868) has released its interim results, with a net loss attributable to shareholders of RMB 3.121 billion, widening by 173.35% year-on-year.
Nativex (01860) has published its interim results for 2026, with revenue reaching USD 1.156 billion, a growth of 23.2% year-on-year.
Leapmotor (09863) has released its interim results, with shareholder profit attributable of RMB 208 million, representing a significant increase of 530.97% year-on-year.
TravelSky Technology (00696) has announced its interim results, with net profit attributable to shareholders at RMB 1.543 billion, up 6.59% year-on-year.
Ming Ming Hen Mang (01768) has released its interim results, with net profit attributable to shareholders of RMB 2.24 billion, up 155.39% year-on-year.
Yuexiu Services (06626) has released its interim results, with shareholder profit attributable of RMB 224 million, as it optimizes its value-added services business layout across all dimensions.
China Resources Pharmaceutical (03320) has announced its interim results, with shareholder profit attributable of RMB 2.187 billion, up 5.3% year-on-year.
Sigenergy New Energy (06656) has published its interim results, with adjusted net profit of approximately RMB 2.485 billion, a rise of 135.8% year-on-year.
Comments